H-FTFSLDTSK-OH

Ref. 3D-PP46502

Informations sur le produit

• Nom: H-FTFSLDTSK-OH
• Synonymes: NH2-Phe-Thr-Phe-Ser-Leu-Asp-Thr-Ser-Lys-OH

Description

Peptide H-FTFSLDTSK-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-FTFSLDTSK-OH include the following: Analysis of therapeutic monoclonal antibody glycoforms by mass spectrometry for pharmacokinetics study Y Cong, L Hu, Z Zhang, Y Gao, M Dong, H Qin, M Ye - Talanta, 2017 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0039914017300206 A new reliable, transposable and cost-effective assay for absolute quantification of total plasmatic bevacizumab by LC-MS/MS in human plasma comparing two R Legeron, F Xuereb , S Chaignepain - of Chromatography B, 2017 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1570023217302969 Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis N Iwamoto, Y Umino, C Aoki, N Yamane - Drug metabolism and , 2016 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1347436715000695 Comparison of bevacizumab quantification results in plasma of non-small cell lung cancer patients using bioanalytical techniques between LC-MS/MS, ELISA, and N Iwamoto, M Takanashi, T Shimada, J Sasaki - The AAPS Journal, 2019 - Springerhttps://link.springer.com/article/10.1208/s12248-019-0369-z What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum? J Vialaret , S Broutin, C Pugnier, S Santele, A Jaffuel - Bioanalysis, 2018 - Future Sciencehttps://www.future-science.com/doi/abs/10.4155/bio-2018-0027 Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma HH Chiu , IL Tsai, YS Lu, CH Lin, CH Kuo - Analytical and bioanalytical , 2017 - Springerhttps://link.springer.com/article/10.1007/s00216-017-0607-0 Optimization and method validation for the quantitative analysis of a monoclonal antibody and its related fab fragment in human plasma after intravitreal administration CE DelGuidice, OA Ismaiel , WR Mylott Jr - of Chromatography B, 2021 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1570023220313507 A fully validated LC"‘MS/MS method for quantifying bevacizumab in plasma samples from patients with NSCLC and its implications in therapeutic drug monitoring B Li, M Yang, X Wang, W Chen, H Lu - Oncology , 2024 - spandidos-publications.comhttps://www.spandidos-publications.com/10.3892/ol.2024.14356 A validated LC-MS/MS method for the quantification of bevacizumab in rat, cynomolgus monkey, and human serum A Zhou, J Yu, Y Wu, H Xue, D Zhong, X Diao - Journal of Pharmaceutical , 2023 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S073170852300359X

• Marque: Biosynth